philblox

philblox CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and Drug Administration (FDA) approval of LYMPHIRTM (denileukin diftitox-cxdl), an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL); Began trading on the Nasdaq exchange under the ticker symbol CTOR on August 13, 2024 , following completion of the merger of Citius Pharma's oncology subsidiary with TenX Keane to form Citius Oncology, Inc., a standalone publicly traded company; Advanced manufacturing, marketing and sales activities in preparation for commercial launch of LYMPHIR in the first half of 2025; key activities included: Manufactured initial inventory for launch and finalized supply chain agreements, Initiated recruitment of targeted field force with contract sales organization, Launched a marketing awareness campaign and engaged with all leading CTCL prescribers, Applied for a unique J-code within the Healthcare Common Procedure Coding System (HCPCS) to facilitate accurate reimbursement, Secured inclusion of LYMPHIR in the National Comprehensive Cancer Network (NCCN) guidelines, critical to clinical decision-making in oncology and hematology, influencing treatment practices and payor reimbursement in the U.S., and Initiated development of the patient support center to help patients access LYMPHIR expeditiously; Supported two investigator-initiated trials to explore LYMPHIR's potential as an immuno-oncology combination therapy being conducted at the University of Pittsburgh Medical Center and the University of Minnesota ; and, Shared interim trial results with the clinical community at the Society for Immunotherapy of Cancer Conference (SITC) of University of Pittsburgh Medical Center's Phase I trial of LYMPHIR with checkpoint inhibitor pembrolizumab. The combination of these two immunomodulatory agents showed clinical benefit in relapsed or refractory gynecological neoplasms, resulting in: 27% objective response rate and 33% clinical benefit rate with median progression free survival of 57 weeks (range: 30-96 weeks), and A manageable safety profile whereby the regimen was well-tolerated with reversible treatment emergent adverse events and no definitive immune-related adverse events greater than or equal to grade 3 documented. Financial Highlights R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 ; G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 ; Stock-based compensation expense was $7.5 million for the full year ended September 30, 2024 , compared to $2.0 million for the full year ended September 30, 2023 ; and, Net loss was $21.1 million , or ($0.31) per share for the full year ended September 30, 2024 compared to a net loss of $12.7 million , or ($0.19) per share for the full year ended September 30, 2023 . "Reflecting on 2024, Citius Oncology has achieved pivotal milestones that underscore our commitment to advancing cancer therapeutics," stated Leonard Mazur , Chairman and CEO of Citius Oncology. "The FDA's approval of LYMPHIR for the treatment of cutaneous T-cell lymphoma marks a significant advancement in providing new options for patients battling this challenging disease. It is the only targeted systemic therapy approved for CTCL patients since 2018 and the only therapy with a mechanism of action that targets the IL-2 receptor. Additionally, the successful merger forming Citius Oncology, now trading on Nasdaq under the ticker CTOR, strengthens our position in the oncology sector. We expect it to facilitate greater access to capital to fund LYMPHIR's launch and the Company's future growth. With a Phase I investigator-initiated clinical trial combining LYMPHIR with pembrolizumab demonstrating promising preliminary results, indicating potential for enhanced treatment efficacy in recurrent solid tumors, and preliminary results expected from a second investigator trial with CAR-T therapies in 2025, we remain excited about the potential of LYMPHIR as a combination immunotherapy." "These accomplishments reflect the dedication of our team and the trust of our investors. As we look ahead, we remain steadfast in our mission to develop innovative therapies that improve the lives of cancer patients worldwide," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Research and Development (R&D) Expenses R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 . The increase reflects development activities completed for the resubmission of the Biologics License Application of LYMPHIR in January 2024 , which were associated with the complete response letter remediation. General and Administrative (G&A) Expenses G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-commercial and commercial launch activities of LYMPHIR including market research, marketing, distribution and drug product reimbursement from health plans and payers. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $7.5 million as compared to $2.0 million for the prior year. The primary reason for the $5.5 million increase was due to the amounts being realized over 12 months in the year ended September 30, 2024 , as compared to three months post-plan adoption in the year ended September 30, 2023 . Net loss Net loss was $21.1 million , or ($0.31) per share for the year ended September 30, 2024 , compared to a net loss of $12.7 million , or ($0.19) per share for the year ended September 30, 2023 . The $8.5 million increase in net loss was primarily due to the increase in our operating expenses. About Citius Oncology, Inc. Citius Oncology specialty is a biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. In August 2024 , its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million , is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals. For more information, please visit www.citiusonc.com Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Oncology are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; risks related to research using our assets but conducted by third parties; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS ONCOLOGY, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 Current Assets: Cash and cash equivalents $ 112 $ — Inventory 8,268,766 — Prepaid expenses 2,700,000 7,734,895 Total Current Assets 10,968,878 7,734,895 Other Assets: In-process research and development 73,400,000 40,000,000 Total Other Assets 73,400,000 40,000,000 Total Assets $ 84,368,878 $ 47,734,895 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 3,711,622 $ 1,289,045 License payable 28,400,000 — Accrued expenses — 259,071 Due to related party 588,806 19,499,119 Total Current Liabilities 32,700,429 21,047,235 Deferred tax liability 1,728,000 1,152,000 Note payable to related party 3,800,111 — Total Liabilities 38,228,540 22,199,235 Stockholders' Equity: Preferred stock - $0.0001 par value; 10,000,000 shares authorized: no shares issued and outstanding — — Common stock - $0.0001 par value; 100,000,000; 71,552,402 and 67,500,000 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,155 6,750 Additional paid-in capital 85,411,771 43,658,750 Accumulated deficit (39,278,587) (18,129,840) Total Stockholders' Equity 46,140,339 25,535,660 Total Liabilities and Stockholders' Equity $ 84,368,878 $ 47,734,895 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 4,925,001 4,240,451 General and administrative 8,148,929 5,915,290 Stock-based compensation – general and administrative 7,498,817 1,965,500 Total Operating Expenses 20,572,747 12,121,241 Loss before Income Taxes (20,572,747) (12,121,241) Income tax expense 576,000 576,000 Net Loss $ (21,148,747) $ (12,697,241) Net Loss Per Share – Basic and Diluted $ (0.31) $ (0.19) Weighted Average Common Shares Outstanding – Basic and Diluted 68,053,607 67,500,000 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Cash Flows From Operating Activities: Net loss $ (21,148,747) $ (12,697,241) Adjustments to reconcile net loss to net cash provided by operating activities: Stock-based compensation expense 7,498,817 1,965,500 Deferred income tax expense 576,000 576,000 Changes in operating assets and liabilities: Inventory (2,133,871) - Prepaid expenses (1,100,000) (5,044,713) Accounts payable 2,422,577 1,196,734 Accrued expenses (259,071) (801,754) Due to related party 14,270,648 14,805,474 Net Cash Provided By Operating Activities 126,353 - Cash Flows From Investing Activities: License payment (5,000,000) - Net Cash Used In Investing Activities (5,000,000) - Cash Flows From Financing Activities: Cash contributed by parent 3,827,944 - Merger, net (2,754,296) - Proceeds from issuance of note payable to related party 3,800,111 - Net Cash Provided By Financing Activities 4,873,759 - Net Change in Cash and Cash Equivalents 112 - Cash and Cash Equivalents – Beginning of Year - - Cash and Cash Equivalents – End of Year $ 112 $ - Supplemental Disclosures of Cash Flow Information and Non-cash Activities: IPR&D Milestones included in License Payable $ 28,400,000 $

Canadian News Companies Sue ChatGPT Maker OpenAI Over Repeat Violation Of Copyright LawsThese Black Friday TV deals are still going strong

Stewart cooked critics with Superwoman strength

In a landmark moment at the on December 2, 2024, the logo of was unveiled by Dr. R.N. Padaria, Joint Director (Extension), ICAR, along with Malakajappa Sarawad, Vice President - Sales & Marketing of Arqivo Crop Solutions; JACS Rao, CEO of the State Medicinal Plants Board, Chhattisgarh; and MC Dominic, Founder & Editor-in-Chief of Krishi Jagran, among other esteemed dignitaries on the dais. The event, held at the IARI Grounds in New Delhi, marked a significant milestone for the agriculture industry, highlighting the collaborative spirit and innovation driving the sector forward. , the parent company of Arqivo, has established itself as a leader in the agrochemical industry. Headquartered in Chennai and operates globally over 90 countries with 9 international subsidiaries across Latin America, Central America, Europe, Middle East & Asia. Tagros has gained an international reputation for delivering high-quality products in and allied segments. The unveiling of Arqivo's logo symbolizes the company's commitment to further enhancing agricultural practices and offering cutting-edge solutions to farmers globally. Tagros operates 4 advanced manufacturing facilities at Dahej, Panoli, Ankleshwar and Cuddalore. These facilities underscore the company's ability to scale operations efficiently, ensuring seamless delivery of world-class agrochemical solutions to customers around the globe. Dr. Ramesh Chand lauded the initiative, highlighting the critical role of innovation in addressing the challenges faced by farmers. He emphasized the importance of partnerships like this in realizing the Prime Minister’s vision of doubling farmers’ incomes and ensuring sustainable agricultural practices. MFOI Samridh Kisan Utsav 2024 in Satna showcased new agricultural innovations to over 225 farmers, featuring displays from Mahindra Tractors,... Tagros' unmatched expertise in manufacturing and commitment to sustainability positions it as a trusted partner for farmers worldwide. By introducing Arqivo Crop Solutions, the company aims to strengthen its portfolio and provide innovative solutions that empower farmers, boost productivity, and contribute to global food security. The launch event also featured a panel discussion on emerging trends in , with prominent speakers emphasizing the need for robust crop protection solutions to meet the demands of a rapidly growing population. Tagros is one of India’s fastest-growing manufacturers of agrochemicals, committed to delivering for global agriculture. With a customer-first approach and cutting-edge technology, the company continues to redefine industry standards, enhancing lives and livelihoods across continents.

Column: Latest nutty idea from MLB Commissioner Rob Manfred — the Golden At-Bat — proves how little he cares about baseball fansCarbon Streaming Announces Board and CEO ChangesBy HALELUYA HADERO, Associated Press President-elect Donald Trump asked the Supreme Court on Friday to pause the potential TikTok ban from going into effect until his administration can pursue a “political resolution” to the issue. The request came as TikTok and the Biden administration filed opposing briefs to the court, in which the company argued the court should strike down a law that could ban the platform by Jan. 19 while the government emphasized its position that the statute is needed to eliminate a national security risk. “President Trump takes no position on the underlying merits of this dispute. Instead, he respectfully requests that the Court consider staying the Act’s deadline for divestment of January 19, 2025, while it considers the merits of this case,” said Trump’s amicus brief, which supported neither party in the case. The filings come ahead of oral arguments scheduled for Jan. 10 on whether the law, which requires TikTok to divest from its China-based parent company or face a ban, unlawfully restricts speech in violation of the First Amendment. Earlier this month, a panel of three federal judges on the U.S. Court of Appeals for the District of Columbia Circuit unanimously upheld the statute , leading TikTok to appeal the case to the Supreme Court. The brief from Trump said he opposes banning TikTok at this junction and “seeks the ability to resolve the issues at hand through political means once he takes office.”ATHENS, Ga. — This one’s going to hurt for a while. Ahead by 17 points at the half, by 14 with four minutes left in regulation, Georgia Tech tasted the most bitter of defeats. And instead of sweet, sweet victory over a most hated rival, instead of stunning a national power for whom a win Friday was widely assumed, the Yellow Jackets and their fan base once again have only heartbreak. What if Tech could have converted a fourth-and-1 (or a third-and-1) from the Georgia 25 early on? What if the Jackets hadn’t missed a 25-yard field-goal attempt in the second quarter? What if the Tech defense could have made only one play to stop any of Georgia’s three fourth-quarter touchdown drives? What if the Jackets could have converted a first down after taking possession of the ball with 3:33 left in regulation and leading 27-20? What if Tech could have scored on either of the two overtime periods when it had the ball second after a failed Bulldogs attempt and could have ended the game with a successful two-point conversion? What if, what if, what if? No. 7 Georgia 44, Georgia Tech 42, eight overtimes. For the seventh consecutive meeting, the Jackets fell to their in-state rivals, this time in a fashion that was like a gut punch followed by a kick to the face and finished off with strangers barking loudly in their face. But what ought not be forgotten in such a crushing defeat was the incontrovertible evidence that Tech has become a team to be reckoned with — in college football, in the ACC and undoubtedly in the state of Georgia. It took Georgia, a national championship contender playing in front of its vaunted home crowd — where it hadn’t lost in its past 30 games — eight overtimes to survive its archrival’s upset attempt. Only once in college football history have two teams played more overtimes, a nine-overtime game between Illinois and Penn State in 2021. That was the degree to which Georgia and Tech were evenly matched. This at the end of a regular season in which the Jackets beat two top-10 teams, won more regular-season games (seven) than they had won since 2018 and earned back-to-back bowl bids for the first time since their 18-year bowl streak ended in the 2015 season. If Georgia goes on to win the national title, the Bulldogs and their fan base will have to look upon that late November night at Sanford Stadium and feel thankful (and perhaps lucky) that the Jackets didn’t have one more play in them. It was so, so close. Entering the game as 17-point underdogs, the Yellow Jackets took control of the game from the start. They drove into Georgia territory on their first five possessions, twice scoring touchdowns, while forcing two punts, a turnover, a fourth-down stop and a missed field-goal attempt in Georgia’s first five times with the ball. They led 17-0 at the half, the first time the Bulldogs had been held scoreless through halftime since 2019. If anyone had doubted Tech’s capacity to take down the Bulldogs before kickoff, the time for disbelief had passed. Tech continued to control the game into the third quarter, with the Jackets answering two Georgia touchdown drives with a field goal and a touchdown. Quarterback Haynes King, his right (throwing) shoulder in much better health than it had been in Tech’s previous two games when his passing ability was severely limited, was at his gritty playmaking best. When he ran in a keeper from 11 yards out that (along with an Aidan Birr point-after try) put the Jackets up 27-13 with 5:37 to play in regulation, it seemed safe for Tech fans to start to celebrate. Indeed, Georgia fans began to leave Sanford Stadium, their expectations of victory dashed. But, as is the history of this one-sided rivalry, the talented Bulldogs had the final say. Georgia drove 75 yards for a touchdown to cut the lead to 27-20 with 3:39 left in the fourth quarter, then forced a fumble out of King on a fateful third-and-1 carry from the Tech 31. It followed another “what if?” — a King pass to receiver Abdul Janneh on second-and-13 in which Janneh was forced out of bounds just shy of the marker. Georgia exploited the mistake and tied the score with a 32-yard touchdown drive that finished with 1:01 left in the fourth quarter. In the wildest back-and-forth struggle in overtime, Georgia and Tech could not be separated, stuck to each other like magnets bound by titanium and sealed in a vacuum. Seven overtimes could not yield a winner. The two teams matched touchdowns and extra points (first overtime), then touchdowns and failed mandatory two-point tries (second overtime), then failed two-point conversion tries (third and fourth overtimes), then successful conversions (fifth overtime), then failed conversions (sixth and seventh overtimes). The seventh had a now-or-never feel for the Jackets. Going first, Georgia was stopped on a Carson Beck keeper when the Bulldogs borrowed from the Tech playbook with a fake toss by Beck and a run up the middle, a King staple. He was stopped short by safety Omar Daniels. Tech could now win with a conversion from the 3-yard line. Tech offensive coordinator Buster Faulkner dug deep from his own cache of plays, lining up both offensive tackles and both guards near the sideline. The resulting pass play yielded a pass interference against Georgia and now the Jackets had the ball at the 1 1/2-yard line. If the Jackets could just punch it in from 54 inches out, victory would be theirs. But King, carrying after a fake handoff, was tackled well short of the goal line. And in the eighth overtime, Georgia finally prevailed. King threw incomplete to receiver Eric Singleton Jr. and then Bulldogs running back Nate Frazier scored on a run up the middle. In the first minutes of Saturday morning, game (finally) over. Some Tech players walked straight to the locker room. King, who had played so valiantly, graciously wandered through the field finding Bulldogs players to congratulate before heading back to the locker room. There is one consolation for Tech and its fan base. Tech must have Georgia’s full attention now. It already had Smart’s. He has seen his colleague Key build this program and claim recruits that the Bulldogs have gone after, something that hasn’t always happened in this state. “This rivalry is good for our state, and that’s what Brent and I shared before the game and after the game,” Smart said. Where recent Tech-Georgia meetings have been so one-sided in the red team’s favor that it barely seemed like a rivalry and losses nothing to lose sleep over, that’s no longer the case. But on this cold night, that might have been about it. ©2024 The Atlanta Journal-Constitution. Visit at ajc.com . Distributed by Tribune Content Agency, LLC.

PACS LEGAL DEADLINE: PACS Group Class Action Deadline is Approaching – Contact BFA Law if You Suffered Losses (NYSE:PACS)By HALELUYA HADERO, Associated Press President-elect Donald Trump asked the Supreme Court on Friday to pause the potential TikTok ban from going into effect until his administration can pursue a “political resolution” to the issue. The request came as TikTok and the Biden administration filed opposing briefs to the court, in which the company argued the court should strike down a law that could ban the platform by Jan. 19 while the government emphasized its position that the statute is needed to eliminate a national security risk. “President Trump takes no position on the underlying merits of this dispute. Instead, he respectfully requests that the Court consider staying the Act’s deadline for divestment of January 19, 2025, while it considers the merits of this case,” said Trump’s amicus brief, which supported neither party in the case. The filings come ahead of oral arguments scheduled for Jan. 10 on whether the law, which requires TikTok to divest from its China-based parent company or face a ban, unlawfully restricts speech in violation of the First Amendment. Earlier this month, a panel of three federal judges on the U.S. Court of Appeals for the District of Columbia Circuit unanimously upheld the statute , leading TikTok to appeal the case to the Supreme Court. The brief from Trump said he opposes banning TikTok at this junction and “seeks the ability to resolve the issues at hand through political means once he takes office.”

Here Is The Best-Selling TV On Amazon During Black Friday, And It Costs Only $69The members of the District Sports Club (DSC) located in Dharavi are up in arms against the club's alleged mismanagement and lack of amenities despite charging hefty fees. The club spread over 12,000 sq mts of prime plot near Bandra Kurla Complex, was constructed at a cost of Rs 21 crore by the state government in 2013 to promote sports activities among the masses. However, the management was handed over to a private firm in 2019 when Vinod Tawde was the minister for sports in the then BJP-led government. The contract was given Oscorp Construction Pvt Ltd despite strong opposition from local people. “In 2019, the management promised to develop the club in three phases. However, apart from minor interior changes, we do not see any change. We are waiting for a basic cafeteria to come up,” said a lifetime member of the club Vishal Karande. Karande is a resident of Dharavi, who took the lifetime membership by paying Rs 3 lakhs in 2019 under the special scheme for locals by the DSC. “I am paying the same coaching fees of Rs 21,000 for 50 swimming sessions for my son which a non-member pays. The management focuses on visiting members to make profit,” he alleged. Another agitated member of the club, Krishna Kumar Jhunjhunwala said, “We are fed up with the management. On my recommendation, several people purchased lifetime memberships. I feel embarrassed whenever those people question me about the condition of the club. I now urge that anyone thinking of taking membership of DSC should rather invest that Rs 10 lakh in a bank fixed deposit. The bank will give good returns!”, Jhunjhunwala said, who is a resident of Pali Hill and a silk trader. The DSC charges now charge Rs 10 lakh for lifetime membership fees, which was Rs 5 lakh in 2019. “We see no development in five years. There is not a cafeteria to take family along. Our money is wasted. The least we expect is an annual meeting to hear the members. But the District Collector is not bothered to look into the matter,” Jhunjhunwala said. The club’s committee is headed by the Mumbai City District Collector Sanjay Yadav and panel members include Dy Director (Sports & Youth) Navnath Fardate and District Sports Officer Suhas Vhanmane, along with the Suraj Samat and Yash Sharda from the private management. The Dharavi Sports Club, also known as Rajiv Gandhi Sports Club was built by MMRDA at the cost of Rs 21 crore and thrown open to the public in 2013. The club provides a gymnasium, swimming pool, squash and badminton courts among others was looked upon as a silent revolution for sports talent in the slums of Dharavi. However, in 2019 the state government roped in a private firm – Oscorp Construction Pvt Ltd to run the club citing that it cannot financially sustain itself. It is not only the members, but even the coaches who are unhappy with the management. “The management at DSC is to make money for themselves rather than provide facilities to its members. Moreover, there is no objective to shape young talent and produce national sportspersons," A.I. Singh, former squash coach at the club alleged. “Of the total coaching fee paid by the student, the management takes 60 percent and the coach gets a mere 40 percent, which is the highest ratio the management gets, probably anywhere in India. The club also takes deposit from the coaches, which is absurd,” Singh, who has produced 14 national champions, said. “The club was initially open to all. The government made the wrong decision to hand it over to a private firm. The objective to find hidden talents among the common masses is lost. We need to promote sports in lower income groups. The sports complex is built by the government by taxpayers money,” said Vishwajeet Shinde, a sports coach from Mumbai, who has also trained Olympic medalist Swapnil Kusale. Yash Sharda from the club management refused to give his comment. The FPJ called Mumbai City collector Sanjay Yadav, who heads the committee at DSC said that he is out of the city and will discuss the matter once he resumes to duty next week.

Pretty much everything that could go wrong for the Ohio State Buckeyes in Week 14 went wrong. Not only did they lose "The Game" to the Michigan Wolverines by a final score of 13-10, but they also got into a massive brawl with Michigan immediately afterwards that could result in several players on both getting suspended. With the Wolverines winning this one late, their players rushed the field when the clock struck zero and planted their flag in the middle of the field. The Buckeyes took exception to this, and ended up starting a full-scale brawl with the Wolverines that quickly caught fans' attention. The aftermath of the fight was pretty messy, and there's a lot that both teams and the NCAA will have to work through as a result. With things still fresh, Ohio State's athletic director Ross Bjork refused to comment on the situation, saying he needed to gather more details on what actually happened. Per Brandon Marcello of CBS Sports, "Ohio State athletics director Ross Bjork declined to comment to CBS Sports when asked about the postgame skirmish. He needs to gather more details on what happened, he said." Ohio State athletics director Ross Bjork declined to comment to CBS Sports when asked about the postgame skirmish. He needs to gather more details on what happened, he said. Considering the scale of the fight, it's not a surprise to see Bjork is waiting for things to clear up before he fully addresses what happened. And beyond the fight, the team also lost a game they desperately needed to win, so it's safe to say there's going to be some soul-searching within Ohio State over the next few days. © Barbara J. Perenic/Columbus Dispatch / USA TODAY NETWORK via Imagn Images Not only did the Buckeyes likely lose their spot in the Big Ten Championship Game to the Penn State Nittany Lions, but their standing in the College Football Playoff rankings is set to tumble as well. There's a chance that this defeat could destroy Ohio State's 2024 campaign. For now, the Buckeyes are reeling in the wake of their defeat and this massive fight, but they still have a chance to salvage their campaign. It will require quite a turnaround, but you can't count Ohio State out just yet, even though things look quite dire in the wake of this crushing defeat. Related: Michigan Trolls Ohio State by Reposting Final Score with Subtle TwistCommission won't hold public meeting over 505 Minmi Road, Fletcher concerns

Kitty McKay: Create memories in the kitchen (recipe)